Info

C. R. Bard, Inc. (Bard) is engaged in the designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells a range of products worldwide to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities. In general, the Company’s products are intended to be used once and then discarded or implanted either temporarily or permanently. Bard has four major product group categories: vascular, urology, oncology and surgical specialties. The Company has a 50% ownership in Medicon, Inc. (Medicon), a Japanese joint venture with Kobayashi Pharmaceutical Co., Ltd. In January 2008, Bard acquired the LifeStent family of stents from Edwards Lifesciences Corporation. These stents are available in the United States for biliary indications only. In June 2008, Specialized Health Products International Inc. completed its merger into a wholly owned subsidiary of Bard.